BiotechTube
Holobiome

Holobiome

Cambridge, United States· Est.
holobiome.org
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $28M

Overview

Holobiome is a private, preclinical-stage biotech leveraging a proprietary platform to mine the human microbiome for novel live biotherapeutic products (LBPs). Founded by research scientists from Northeastern University, the company is advancing a pipeline focused on neurological and other systemic conditions through a rigorous discovery and development process. With a strong scientific team and advisory board, Holobiome has attracted strategic partners and investors to fund its translation of cutting-edge microbiome research into potential therapies. The company operates in the high-growth but technically challenging microbiome therapeutics sector.

Neurological DisordersPsychiatric DisordersGastrointestinal DiseasesMetabolic Disorders

Technology Platform

Proprietary platform integrating advanced microbial culturing (to isolate novel gut bacteria), computational biology/bioinformatics, and mechanistic screening to discover and develop defined consortia of bacteria as live biotherapeutic products (LBPs).

Funding History

2
Total raised:$28M
Series A$20M
Seed$8M

Opportunities

The large and growing market for microbiome-based therapeutics, particularly in high-need areas like neuropsychiatry and metabolic diseases where current treatments are inadequate, presents a significant opportunity.
Holobiome's defined consortia approach aligns with a clearer regulatory pathway for biologics, offering potential for strong IP protection and premium pricing as a prescription therapy.

Risk Factors

Key risks include the substantial scientific challenge of proving causality and developing effective live biotherapeutic products, navigating an evolving and complex regulatory landscape for microbiome drugs, and intense competition from other well-funded biotechs in the space, some of which have faced clinical setbacks.

Competitive Landscape

Holobiome competes in the microbiome therapeutics space with companies like Seres Therapeutics, Vedanta Biosciences, Finch Therapeutics, and many others. Its differentiation lies in its focus on the gut-brain axis, its proprietary culturing technology for novel strains, and its strategy of designing defined microbial consortia. The competitive landscape is intense and capital-intensive, requiring robust clinical validation to succeed.

More companies in United States →